Screener
Generate Biomedicines, Inc. GENB Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Generate Biomedicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Generate Biomedicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336437
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Other long term liabilities | (117) | (175) |
| Accrued expenses and other liabilities | (16,888) | 419 |
| Deferred revenue | (13,538) | (18,948) |
| Net cash used in operating activities | (138,332) | (101,929) |
| Investing activities | ||
| Purchase of marketable securities | (321,759) | (142,508) |
| Purchases of property and equipment | (4,714) | (905) |
| Proceeds from sales and maturities of marketable securities | 99,850 | 201,877 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Generate Biomedicines, Inc.'s operating cash flow?
- Generate Biomedicines, Inc. (GENB) reported operating cash flow of -$57.94M in Q2 2026.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Generate Biomedicines, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude